Compare Cronos Group Inc (CRON) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Goldman Sachs Group Inc — how do they compare? Cronos Group Inc trades at $3.05 (market cap $1.11B), while Goldman Sachs Group Inc trades at $1,034.01 (market cap $301.22B). The key difference: Goldman Sachs Group Inc is far larger — about 271.4× Cronos Group Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | GS | |
|---|---|---|
Market Cap | $1.11B | $301.22B |
Sector | Health | Financials |
52-Week High | $3.27 | $1.15K |
52-Week Low | $2.30 | $715.95 |
Enterprise Value | $310.67M | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Goldman Sachs (GS) trades at $1,039.61, up 0.68% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $20.98 surpassing expectations of $14.47. Revenue grew to $58.28 billion in 2025, and net income margin improved to 31.68%. Analysts maintain a consensus price target of $1,160, with 40% recommending Buy. Recent news highlights GS's role in leading high-profile IPOs, including Anthropic, signaling robust investment banking activity.
The outlook for GS is positive, driven by earnings momentum and strategic positioning in key deals. Risks include volatile cash flows, with operating cash flow negative in 2025, and reliance on capital markets activity. Investor sentiment is cautiously optimistic, supported by analyst targets above the current price, but macroeconomic shifts could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
